News

Fierce Biotech21h
Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs
Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...
Gilead to buy certain Hookipa Pharma assets for up to $10M
Antimicrobial drug developer HOOKIPA Pharma (NASDAQ:HOOK) announced Thursday that Gilead Sciences (NASDAQ:GILD) has agreed to ...